Allergan and Editas exercise CRISPR option

Editas Medicine and Allergan Pharmaceuticals have exercised their option for Editas' CRISPR drug. Allergan will develop and commercialize EDIT-101 globally, and Editas will co-develop and share profits and losses in the U.S.